Bokyung Kim

Bokyung Kim

Auto-generated profile, based on publicly available information

Bokyung Kim

Department of Internal Medicine, Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
JSJae Yeon Sim
Jae Yeon Sim
HCHyunsoo Chung
Hyunsoo Chung
SKSang Gyun Kim
Sang Gyun Kim
SCSoo-Jeong Cho
Soo-Jeong Cho
BKBo Kyung Kim
Bo Kyung Kim
IKinho kim
inho kim
Sim JY, et al. J Gastric Cancer. 2024 Sep;24:e36. https://doi.org/10.5230/jgc.2024.24.e36

21 March 2024 in Gut and Liver
Verified
Journal Article
Open access
PDF file
SLSeunghan Lee
Seunghan Lee
SCSoo-Jeong Cho
Soo-Jeong Cho
HCHyunsoo Chung
Hyunsoo Chung
BKBokyung Kim
Bokyung Kim
MOMi Jin Oh
Mi Jin Oh
SKSang Gyun Kim
Sang Gyun Kim
Seunghan Lee, Soo-Jeong Cho, Hyunsoo Chung, Bokyung Kim, Mi Jin Oh, Yun Suk Na, Jun Hee Lee, Jiyoon Kim, Sang Gyun Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl230383

10 December 2023 in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Verified
Journal Article
Open access
PDF file
GPGihong Park
Gihong Park
BKBokyung Kim
Bokyung Kim
HCHyunsoo Chung
Hyunsoo Chung
SKSang Gyun Kim
Sang Gyun Kim
SCSoo-Jeong Cho
Soo-Jeong Cho
Objectives: The A2142G and A2143G mutations in the 23S ribosomal ribonucleic acid (rRNA) of Helicobacter pylori are the most common mutations associated with clarithromycin resistance. This study aimed to determine the differences in H. pylori eradication rates in patients infected with bacteria carrying the A2142G and A2143G mutations who were treated with clarithromycin-based triple therapy. Methods: Data from a previous randomized controlled trial were analyzed retrospectively. Eradication rates were compared based on the presence of H. pylori carrying the A2142G and A2143G mutations. A meta-analysis was also conducted of relevant studies containing data regarding patients who received clarithromycin-based therapy due to infections with H. pylori harboring 23S rRNA mutations. Results: No significant difference was observed in H. pylori eradication rates between patients infected with wild-type bacteria (95.7% [44/46]) compared with those infected with bacteria carrying the A2142G mutation (100.0% [3/3]; p>0.9). However, the eradication rate was significantly lower for patients infected with bacteria carrying the A2143G mutation (16.7% [1/6]; p<0.001) than for those infected with wild-type bacteria or bacteria with the A2142G mutation (100.0% [3/3]; p=0.048). In the meta-analysis, the between-group comparisons yielded similar results. Although patients infected with bacteria having the A2142G mutation exhibited no significant risk difference (RD) for eradication compared with those infected with wild-type bacteria (RD=-0.05 [-0.18 to 0.08]; I2=0%; p=0.42), those infected with bacteria having the A2143G mutation demonstrated a lower H. pylori eradication rate compared with patients infected with either wild-type (RD=0.72 [0.64–0.80]; I2=0%; p<0.001) or A2143G mutant bacteria (RD=0.76 [0.61–0.91]; I2=0%; p< 0.001). Conclusions: The A2143G mutation may play a more significant role in clarithromycin triple therapy H. pylori eradication failure than does the A2142G mutation. Additionally, H. pylori strains with the A2142G mutation can be treated effectively with clarithromycin-based triple therapy.

9 July 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MOMi Jin Oh
Mi Jin Oh
SKSang Gyun Kim
Sang Gyun Kim
JKJiyoon Kim
Jiyoon Kim
YNYun Suk Na
Yun Suk Na
SLSeunghan Lee
Seunghan Lee
SCSoo-Jeong Cho
Soo-Jeong Cho
Background: Although several small cohort studies have shown the utility of argon plasma coagulation (APC) in the treatment of gastric dysplasia, its clinical significance has not been established. This study aims to assess the efficacy of APC as a first line treatment for gastric dysplasia, and identify risk factors for residual dysplasia. Methods: A total of 179 cases of gastric dysplasia were treated with APC and have been followed-up with upper endoscopy within 1 year. The overall incidence and the characteristics of lesions with residual dysplasia in follow-up endoscopy were analyzed by logistic regression. Results: Among 179 lesions treated with APC, 171 (95.5%) lesions have achieved complete ablation in the follow-up endoscopy. Additional APC was applied for residual dysplasia, achieving complete ablation in 97.77% (175/179). The upper third location of the gastric dysplasia was significantly associated with residual dysplasia, while tumor size, horizontal location, macroscopic morphology and grade of dysplasia showed no significant associations with residual dysplasia following the initial APC. Conclusions: APC with meticulous follow-up can be recommended as a first line treatment in patients with gastric dysplasia.

1 January 2021 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
ENEnerelt Natsagdorj
Enerelt Natsagdorj
SKSang Gyun Kim
Sang Gyun Kim
JCJinju Choi
Jinju Choi
SKSeungkyung Kang
Seungkyung Kang
BKBokyung Kim
Bokyung Kim
SCSoo-Jeong Cho
Soo-Jeong Cho
Natsagdorj E, et al. J Gastric Cancer. 2021 Sep;21(3):258-267. https://doi.org/10.5230/jgc.2021.21.e25

18 July 2025 in Gut and Liver
Verified
Journal Article
Open access
PDF file
BKBokyung Kim
Bokyung Kim
JHJung Huh
Jung Huh
SKSang Gyun Kim
Sang Gyun Kim
JAJi Yong Ahn
Ji Yong Ahn
JKJi Won Kim
Ji Won Kim
Bokyung Kim, Jung Huh, Sang Gyun Kim, Ji Yong Ahn, Ji Won Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250267